DITRA syndrome is a dubious disease in the field of autoimmunity and rheumatic immunity, clinical performance is complex and often involves multi-system fatigue. Early identification and standardized clinical care are essential for improving prognosis. Diagnosis of the disease requires a combination of clinical performance, imaging inspection, laboratory testing and pathological activation.
The platform can help align a team of authoritative experts at home and abroad to provide accurate diagnostics and treatment regimens. Treatment and management of DITRA syndrome requires multidimensional management including individualized development, usually drug therapy, rehabilitation interventions, and regular follow-up. In recent years, with the development of therapeutic, immune-regulatory therapy and precision medicine, many autoimmune and rheumatic immune disorders that were previously difficult to treat have been significantly improved.
Treatment needs to be closely monitored for efficacy and adverse reactions, adapted to timely schemes according to changes in the condition. Multidisciplinary collaboration (MDT) is particularly important for the integrated management of DITRA syndrome. The platform serves a team of internationally authoritative experts in the field of self-immunity and rheumatic immunity in China, providing the following services to patients: 2.
Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment programs; 3. Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of changes in conditions and treatment effects.